It's possible he was
saying AAV re-dosing is possible today. QURE doesn't seem overly
concerned about moderate levels of antibodies to their AAV5 vector (based on NHP studies):
Later T-cell response against transfected cells could possibly be controlled with immunosuppressive steroids like is done now for initial dosing.
Right
now, researchers are being cautious to avoid treating those with
existing immunity to specific AAV vectors, but we won't know the full
story for real until re-dosing is tried in humans with the same AAV
vector.
Interesting paper about AAV re-dosing,
"the elephant in the room" of gene therapy, using SVP-rapamycin in
animals, co-administered with initial AAV to prevent antibodies and T-cell responses, thus allowing re-dosing:
Here is one of the publications from Selecta Bio:
Interesting that this effect is mediated by TRegs: